Global Medical Directory is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Connect with this vendor - Learn about this product

DEXELL VUR - Endoscopic treatment of Vesico Uretheral Reflux

Endoscopic treatment with Dextranomer/Hyaluronic acid substances has become increasingly popular for managing VUR and it is the most widely used tissue-augmenting substance. Endoscopic treatment has several advantages. In contrast to long-term antibiotic prophylaxis, it offers immediate cure of reflux at a high incidence, its success does not rely on patient or parent compliance, and the procedure is virtually free of adverse side effects. Long-term administration of antibiotics implies the danger of bacterial resistance with promotion of breakthrough urinary tract infections, and antibiotics are usually needed for years.

DEXELL consists of a suspension of positively charged dextranomer microparticles and cross-linked hyaluronic acids of non animal origin.

The cross-linked hyaluronic acid (Hylan gel) primarily functions as a means of transportation for the dextranomer microparticles which stimulate the connective tissue at the place of injection. Both the Hylan gel as well as the dextranomer microparticles of DEXELL are biodegradable and biocompatible.